Zephyrus Innovations® Receives Strong Customer Response Following VaporShield® CSTD System Pre-Commercial Workshops
News originally published by
EIN PresswireZephyrus Innovations announces that it has successfully conducted pre-commercial training workshops and evaluations across key US strategic accounts.
VANCOUVER, CANADA, November 13, 2026 /EINPresswire.com/ --- VaporShield is the World’s first direct injection CSTD for subcutaneous and intramuscular administration
- VaporShield is an end-to-end closed system which prevents splattering, spraying and aerosolization of drugs
- Over 50 healthcare professionals participated in hands-on VaporShield demonstrations and evaluations
- 100% of those surveyed said VaporShield would offer better protection than current devices.
Zephyrus Innovations (Zephyrus), a privately-owned medical device company designing and manufacturing safety syringes and Closed System Transfer Devices (CSTDs), today announces that it has successfully conducted pre-commercial VaporShield CSTD System training workshops and product evaluations across several key US strategic hospital accounts. This comes ahead of entering full commercialisation. The team engaged with more than 50 pharmacists, medication safety officers, nurse administrators and other healthcare professionals working across multiple healthcare disciplines.
During the first week of November 2026, workshops took place at hospitals and cancer centres in Ohio, where growing interest in hazardous drug protection has created opportunities to engage with healthcare teams around the application of USP<800>. The programme included educational presentations, product demonstrations and hands-on evaluations, allowing customers to experience the VaporShield CSTD System first-hand.
Tom Crockett, Head of Sales & Marketing at Zephyrus Innovations, commented: “The feedback has been overwhelmingly positive. 100% of users surveyed thought that the VaporShield CSTD System would offer better protection than their current system, and would be happy to introduce this innovation into clinical practice.”
Will Wijnberg, Chief Executive Officer of Zephyrus Innovations, added: “We are incredibly pleased with the response from customers. These workshops have been an important opportunity to demonstrate the product, listen to healthcare professionals and understand their needs. We are looking forward to the next few weeks as we progress towards taking VaporShield into commercial pilot programmes.”
For further information:
www.zephyrusinnovations.com
Email: info@zephyrusinnovations.com
Tom Crockett, James Mainwaring
About Zephyrus
Zephyrus Innovations is a privately-owned medical device company designing and manufacturing safety syringes and CSTDs that deliver medication effectively while protecting clinicians from harmful drug exposure and needlestick injuries, which can lead to infection with bloodborne pathogens and serious disease.
James Mainwaring
Zephyrus Innovations Inc
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

